 | • レポートコード：MRC2-11QY11379 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は循環腫瘍細胞（CTC）予後技術のグローバル市場について調査・分析したレポートです。種類別（腫瘍細胞濃縮、腫瘍細胞検出）市場規模、用途別（前立腺がん、乳がん、大腸がん、肺がん、卵巣がん、膵臓がん）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別循環腫瘍細胞（CTC）予後技術の競争状況、市場シェア ・世界の循環腫瘍細胞（CTC）予後技術市場：種類別市場規模 2015年-2020年（腫瘍細胞濃縮、腫瘍細胞検出） ・世界の循環腫瘍細胞（CTC）予後技術市場：種類別市場規模予測 2021年-2026年（腫瘍細胞濃縮、腫瘍細胞検出） ・世界の循環腫瘍細胞（CTC）予後技術市場：用途別市場規模 2015年-2020年（前立腺がん、乳がん、大腸がん、肺がん、卵巣がん、膵臓がん） ・世界の循環腫瘍細胞（CTC）予後技術市場：用途別市場規模予測 2021年-2026年（前立腺がん、乳がん、大腸がん、肺がん、卵巣がん、膵臓がん） ・北米の循環腫瘍細胞（CTC）予後技術市場分析：米国、カナダ ・ヨーロッパの循環腫瘍細胞（CTC）予後技術市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの循環腫瘍細胞（CTC）予後技術市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の循環腫瘍細胞（CTC）予後技術市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの循環腫瘍細胞（CTC）予後技術市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AdnaGen、ACDBio、Celula、Epic Sciences、Fluxion Biosciences、Rarecells、Silicon Biosystems、Vitatex ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.
Market Analysis and Insights: Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market size is projected to reach US$ 1496.7 million by 2026, from US$ 1294.1 million in 2020, at a CAGR of 14.9%% during 2021-2026.
Global Circulating Tumor Cells (CTCs) Prognostic Technologies Scope and Market Size
Circulating Tumor Cells (CTCs) Prognostic Technologies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
Market segment by Type, the product can be split into
Tumor Cell Enrichment
Tumor Cell Detection
Market segment by Application, split into
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue
1.4 Market by Type
1.4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tumor Cell Enrichment
1.4.3 Tumor Cell Detection
1.5 Market by Application
1.5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application: 2020 VS 2026
1.5.2 Prostate Cancer
1.5.3 Breast Cancer
1.5.4 Colorectal Cancer
1.5.5 Lung Cancer
1.5.6 Ovarian Cancer
1.5.7 Pancreatic Cancer
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Perspective (2015-2026)
2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Growth Trends by Regions
2.2.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Share by Regions (2015-2020)
2.2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Strategy
2.3.6 Primary Interviews with Key Circulating Tumor Cells (CTCs) Prognostic Technologies Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Market Size
3.1.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Revenue (2015-2020)
3.1.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Players (2015-2020)
3.1.3 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio
3.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2019
3.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players Head office and Area Served
3.4 Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Product Solution and Service
3.5 Date of Enter into Circulating Tumor Cells (CTCs) Prognostic Technologies Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Type (2015-2020)
4.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
5.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
6.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in North America (2019-2020)
6.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
6.4 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
7.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Europe (2019-2020)
7.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
7.4 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
8 China
8.1 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
8.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in China (2019-2020)
8.3 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
8.4 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
9 Japan
9.1 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
9.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Japan (2019-2020)
9.3 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
9.4 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
10.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
10.4 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
11 India
11.1 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
11.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in India (2019-2020)
11.3 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
11.4 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
12.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Central & South America (2019-2020)
12.3 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
12.4 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AdnaGen
13.1.1 AdnaGen Company Details
13.1.2 AdnaGen Business Overview
13.1.3 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.1.4 AdnaGen Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020))
13.1.5 AdnaGen Recent Development
13.2 ACDBio
13.2.1 ACDBio Company Details
13.2.2 ACDBio Business Overview
13.2.3 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.2.4 ACDBio Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.2.5 ACDBio Recent Development
13.3 Celula
13.3.1 Celula Company Details
13.3.2 Celula Business Overview
13.3.3 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.3.4 Celula Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.3.5 Celula Recent Development
13.4 Epic Sciences
13.4.1 Epic Sciences Company Details
13.4.2 Epic Sciences Business Overview
13.4.3 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.4.4 Epic Sciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.4.5 Epic Sciences Recent Development
13.5 Fluxion Biosciences
13.5.1 Fluxion Biosciences Company Details
13.5.2 Fluxion Biosciences Business Overview
13.5.3 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.5.4 Fluxion Biosciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.5.5 Fluxion Biosciences Recent Development
13.6 Rarecells
13.6.1 Rarecells Company Details
13.6.2 Rarecells Business Overview
13.6.3 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.6.4 Rarecells Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.6.5 Rarecells Recent Development
13.7 Silicon Biosystems
13.7.1 Silicon Biosystems Company Details
13.7.2 Silicon Biosystems Business Overview
13.7.3 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.7.4 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.7.5 Silicon Biosystems Recent Development
13.8 Vitatex
13.8.1 Vitatex Company Details
13.8.2 Vitatex Business Overview
13.8.3 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.8.4 Vitatex Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.8.5 Vitatex Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Circulating Tumor Cells (CTCs) Prognostic Technologies Key Market Segments
Table 2. Key Players Covered: Ranking by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue
Table 3. Ranking of Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Tumor Cell Enrichment
Table 6. Key Players of Tumor Cell Detection
Table 7. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Regions (2015-2020)
Table 11. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Strategy
Table 17. Main Points Interviewed from Key Circulating Tumor Cells (CTCs) Prognostic Technologies Players
Table 18. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Players (2015-2020) (Million US$)
Table 19. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Players (2015-2020)
Table 20. Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies as of 2019)
Table 21. Global Circulating Tumor Cells (CTCs) Prognostic Technologies by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Product Solution and Service
Table 24. Date of Enter into Circulating Tumor Cells (CTCs) Prognostic Technologies Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020) (Million US$)
Table 27. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Share by Type (2015-2020)
Table 28. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Type (2021-2026)
Table 29. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Share by Application (2015-2020)
Table 30. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020) (Million US$)
Table 31. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Share by Application (2021-2026)
Table 32. North America Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share (2019-2020)
Table 34. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020) (Million US$)
Table 35. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2015-2020)
Table 36. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020) (Million US$)
Table 37. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2015-2020)
Table 38. Europe Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share (2019-2020)
Table 40. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2015-2020)
Table 42. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2015-2020)
Table 44. China Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (2019-2020) (Million US$)
Table 45. China Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share (2019-2020)
Table 46. China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020) (Million US$)
Table 47. China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2015-2020)
Table 48. China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020) (Million US$)
Table 49. China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2015-2020)
Table 50. Japan Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share (2019-2020)
Table 52. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2015-2020)
Table 54. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share (2019-2020)
Table 58. Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2015-2020)
Table 60. Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2015-2020)
Table 62. India Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (2019-2020) (Million US$)
Table 63. India Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share (2019-2020)
Table 64. India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020) (Million US$)
Table 65. India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2015-2020)
Table 66. India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020) (Million US$)
Table 67. India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share (2019-2020)
Table 70. Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type (2015-2020)
Table 72. Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application (2015-2020)
Table 74. AdnaGen Company Details
Table 75. AdnaGen Business Overview
Table 76. AdnaGen Product
Table 77. AdnaGen Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020) (Million US$)
Table 78. AdnaGen Recent Development
Table 79. ACDBio Company Details
Table 80. ACDBio Business Overview
Table 81. ACDBio Product
Table 82. ACDBio Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020) (Million US$)
Table 83. ACDBio Recent Development
Table 84. Celula Company Details
Table 85. Celula Business Overview
Table 86. Celula Product
Table 87. Celula Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020) (Million US$)
Table 88. Celula Recent Development
Table 89. Epic Sciences Company Details
Table 90. Epic Sciences Business Overview
Table 91. Epic Sciences Product
Table 92. Epic Sciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020) (Million US$)
Table 93. Epic Sciences Recent Development
Table 94. Fluxion Biosciences Company Details
Table 95. Fluxion Biosciences Business Overview
Table 96. Fluxion Biosciences Product
Table 97. Fluxion Biosciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020) (Million US$)
Table 98. Fluxion Biosciences Recent Development
Table 99. Rarecells Company Details
Table 100. Rarecells Business Overview
Table 101. Rarecells Product
Table 102. Rarecells Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020) (Million US$)
Table 103. Rarecells Recent Development
Table 104. Silicon Biosystems Company Details
Table 105. Silicon Biosystems Business Overview
Table 106. Silicon Biosystems Product
Table 107. Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020) (Million US$)
Table 108. Silicon Biosystems Recent Development
Table 109. Vitatex Business Overview
Table 110. Vitatex Product
Table 111. Vitatex Company Details
Table 112. Vitatex Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020) (Million US$)
Table 113. Vitatex Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Type: 2020 VS 2026
Figure 2. Tumor Cell Enrichment Features
Figure 3. Tumor Cell Detection Features
Figure 4. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application: 2020 VS 2026
Figure 5. Prostate Cancer Case Studies
Figure 6. Breast Cancer Case Studies
Figure 7. Colorectal Cancer Case Studies
Figure 8. Lung Cancer Case Studies
Figure 9. Ovarian Cancer Case Studies
Figure 10. Pancreatic Cancer Case Studies
Figure 11. Circulating Tumor Cells (CTCs) Prognostic Technologies Report Years Considered
Figure 12. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Regions: 2020 VS 2026
Figure 14. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Players in 2019
Figure 17. Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2019
Figure 19. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
循環腫瘍細胞（CTC）＆がん幹細胞の世界市場（～2026年） The tumor cells which have shed into lymphatic system and circulated over the body through blood circulation are called as circulating tumor cells. Circulating tumor cells may comprise seeds for metastasis. Stem cells are the type of cells that can differentiate into specialized cells and have the c…- 循環腫瘍細胞（CTC）の世界市場（～2026年） Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potenti…
- リキッドバイオプシー用循環バイオマーカーの世界市場（～2026年） Market Analysis and Insights: Global Circulating Biomarker for Liquid Biopsy Market The global Circulating Biomarker for Liquid Biopsy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Circulating Biomarker for Liquid Bi…
- 腫瘍バイオマーカー検査の世界市場（～2026年） Market Analysis and Insights: Global Tumor Biomarker Test Market The global Tumor Biomarker Test market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Tumor Biomarker Test Scope and Market Size Tumor Biomarker Test market is…
- 性腺性腺間質腫瘍の世界市場（～2026年） The sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal component of the ovary and testis. This tumor comprises granulosa, thecal cells, and fibrocytes. Sex cord-gonadal stromal tumors are mostly of seven types, namely, granulosa cell tumor, Sertoli cell tumor, thecoma, …